The role of 18 F-FDG PET/CT for planning the treatment of highgrade salivary gland malignancies was investigated and was compared with that with using contrast-enhanced CT. Methods: The subjects chosen for the study had high-grade cancer of the salivary gland, as confirmed by surgical pathology. The diagnostic values from 37 CT and PET/CT scans of 33 subjects were compared. The ability to predict the extent of the disease was compared by performing a subsite-based analysis for the primary lesions and a level-by-level analysis for the neck node levels as well as for the final TNM staging. The surgical pathology (67.6%) and clinical follow-up examinations (32.4%) were used as the reference standards. Furthermore, the changes made in each subject's care, based on a PET/CT examination, were compared with the treatment received without using the PET/CT data. Results: Using a primary subsite-based analysis, the diagnostic accuracy for predicting the pathologic tumor extent was significantly higher for PET/CT (91.0%) compared with that using CT alone (70.1%, P , 0.001). For the neck nodes on a level-bylevel analysis, the metastasis could be predicted more accurately on the basis of a PET/CT examination (97.6%) than with using only CT (86.0%, P 5 0.01). PET/CT was also far superior to CT in terms of the TNM staging (83.7% vs. 62.1%, P 5 0.03). For 43.2% of the subjects, changes in the clinical decision making were made as a result of the PET/CT scan data over what was previously determined by using the CT scans alone. Conclusion: PET/CT provides more accurate diagnostic information for the evaluation of high-grade salivary cancer than does CT and it has a major impact on making treatment decisions for patients with a high-grade salivary malignancy.
Sal ivary gland malignancies are rare neoplasms and they comprise ,0.5% of all malignancies and about 5% of the cancers of the head and neck (1) . Although many factors affect the prognosis of patients with salivary gland cancer, the 2 most significant factors are known to be the histologic tumor grade and the clinical stage at presentation (2, 3) . To achieve an acceptable treatment outcome for high-grade cancer of the salivary gland, it is essential to accurately evaluate the extent of the disease before deciding on the treatment regimen. Thus, various factors such as local invasion of the primary tumors, regional lymph node metastasis, and distant spread of disease need to be assessed.
The conventional pretreatment work-up for salivary gland cancer depends primarily on the information gleaned from contrast-enhanced CT scans and MRI scans. Some studies have reported that CT and MRI provide a similar diagnostic accuracy with respect to the presurgical planning (4) (5) (6) , although other studies have reported that MRI is superior to CT (7, 8) . CT has high sensitivity (.90%), but it has relatively low specificity (around 60%), with respect to its ability to distinguish between benign and malignant tumors of the salivary gland (4) . However, on the basis of the information from various signal intensities, MRI is superior to CT in terms of sensitivity (nearly 100%) and specificity (80%), in distinguishing benign from malignant tumors (9) . 18 F-FDG PET has been reported to be more accurate than CT or MRI for the detection of malignant tissues, whereas the glucose uptake levels show a good correlation with the histologic grading for head and neck cancer (10) . However, for salivary gland cancer, 18 F-FDG PET shows low accuracy for distinguishing between benign and malignant tumors as benign tumors such as pleomorphic adenoma and Warthin's tumors also have high glucose uptake values (11) (12) (13) (14) . According to these studies, the role of 18 F-FDG PET for the diagnosis of salivary gland cancer is disappointing. Integrated 18 F-FDG PET/CT is also poor at distinguishing between benign and malignant tumors of the salivary gland (15) . By contrast, another study recently concluded that 18 F-FDG PET does have a significant impact on the management of patients with salivary gland cancers for both the initial staging and the restaging (16) . Moreover, 18 F-FDG PET could detect cervical lymph node metastases more accurately and it could detect distant metastases and second primary tumors that could not be detected with using a conventional imaging approach (16) .
However, little information is available on the diagnostic role of PET/CT for high-grade salivary cancers. For highgrade salivary gland cancers, accurate information relating to the tumor's extent and its spread is very important for planning treatment (17) . Accordingly, in this study, the role of integrated 18 F-FDG PET/CT in the management of salivary gland cancer was investigated, with a focus on high-grade tumors, and this was compared with that using contrast-enhanced CT.
MATERIALS AND METHODS
Approval of the Institutional Review Board of Samsung Medical Center was obtained for this study. Patient informed consent was not required for this retrospective analysis, but written informed consent was obtained from all patients for performing the integrated 18 F-FDG PET/CT and contrast-enhanced CT scans.
Subjects
Thirty-five subjects with high-grade salivary carcinoma were retrieved from the Salivary Gland Malignancy Data Registry at Samsung Medical Center (2002) (2003) (2004) (2005) . All pathologic diagnoses were reconfirmed by intradepartment consultations, and the equivocal subjects were discussed with other pathologists to confirm the final pathologic diagnoses. Two subjects were excluded from the pathologic review because the surgical pathology did not meet the criteria of high-grade malignancy of the salivary gland (they were intermediate-grade mucoepidermoid carcinomas). For 14 subjects, high-grade malignancies were prediagnosed on the basis of cytologic analyses, and surgical pathology reconfirmed the high-grade cancer status after surgery. For the remaining 23 subjects, the pathologic diagnoses of high-grade malignancy were confirmed after surgery. Finally, 33 subjects with high-grade salivary carcinoma were included in the analyses, and a total of 37 PET/CT scans with contrast-enhanced CT were obtained (Table 1) . Twenty-three imaging studies were performed to evaluate recurrence during the follow-up period, whereas 14 imaging studies were aimed at arriving at the initial diagnosis. Twentythree PET/CT studies for the evaluation of recurrence were performed on 19 patients. All patients underwent surgical treatment as an initial therapy, and the mean duration between the initial treatment and the PET/CT study ranged from 1 to 180 mo (median, 16 mo). In 6 patients, malignancy was not suggested before the surgery; therefore, PET/CT was performed 1 mo after surgery. Among a total of 37 PET/CT studies, the reference standards were surgical specimens in 25 studies, including 19 patients who underwent neck dissection with or without surgical treatment of the salivary glands. The rest of the studies relied on the clinical follow-up along with the physical examination and other imaging modalities.
The pathologic diagnoses consisted of 5 salivary duct carcinomas, 6 high-grade mucoepidermoid carcinomas, 10 solid-type adenoid cystic carcinomas, 3 squamous cell carcinomas, 3 adenocarcinomas, and 6 carcinoma ex pleomorphic adenoma. The patients' ages ranged from 31 to 83 y (mean, 54.48 y); 22 patients were male and 11 were female. The majority of the primary salivary cancers arose from the parotid gland (66.7%), whereas some were from the submandibular gland (21.2%) and the minor salivary glands (12.1%), including those in the lip and soft palate and 2 sublingual glands. The initial T classifications of the subjects were T1-T2 for 19 patients and T3-T4 for 14 patients. At the initial diagnosis, N0-N1 was the most frequent nodal status of the subjects (81.8%); however, distant metastasis (lung, iliac bone, and paraaortic lymph nodes) was detected in 7 patients (21.2%). During the follow-up, another patient was detected to have distant metastasis on PET/CT.
All patients without distant metastasis were subjected to curative surgical resection with postoperative radiation therapy, whereas 7 patients with distant metastasis underwent palliative chemotherapy. As for the treatment outcome, 18 patients (54.5%) had distant metastasis (lung, liver, bone, abdominal lymph nodes), including 8 subjects that were diagnosed by PET/CT. Unfortunately, PET/CT was not performed on the remaining 10 patients when distant metastasis was detected with the help of conventional studies, so comparative analysis was not available. The average follow-up period of the study was 24.3 mo (range, 12-47 mo).
Contrast-Enhanced CT Scans
CT scans (LightSpeed Ultra or Ultra 16; GE Healthcare) of the head and neck, focusing on the sites of the salivary gland, were performed using the following parameters: 160 mAÁs, 120 keV, a section width of 3.75 mm, and a table feed of 8.75 mm per rotation. For contrast enhancement, 90 mL of an iodinated contrast agent (Iopromide, Ultravist 300; Schering) were injected intravenously at 3 mL/s using an automated injector. The scan delay time was 30 s.
Integrated 18 F-FDG PET/CT Scans
All patients fasted for at least 6 h before PET/CT, which were performed using a Discovery LS PET/CT scanner (GE Healthcare). Whole-body CT was performed by a continuous spiral technique and using 8-slice helical CT with a gantry rotation speed of 0.8 s. The CT scan data were collected using the following parameters: 80 mAÁs, 140 keV, a section width of 5 mm, and a table feed of 5 mm per rotation. No intravenous or oral contrast agents were used. After the CT scans and after injecting 370 MBq 18 F-FDG intravenously, an emission scan was performed from the thigh to the head for 5 min per frame, for a total of 45 min. The duration of the uptake phase was 45 min. The attenuationcorrected 18 F-FDG PET images were reconstructed using the CT data with an ordered-subset expectation maximization algorithm (28 subsets, 2 iterations). The images were displayed in a 128 · 128 matrix (pixel size 5 4.29 · 4.29 mm, with a slice thickness of 4.25 mm). The separate CT and PET scan data were coregistered accurately using commercial software (eNTEGRA; Elgems). The standardized uptake values (SUVs) were acquired using the attenuation-corrected images, the amount of injected 18 F-FDG, the body weight of each patient, and the cross-calibration factors between 18 F-FDG PET and the dose calibrator.
Image Analysis
For the subsite-based analysis, we divided the structures around the salivary gland into subsites according to the American Joint Committee on Cancer Staging (AJCC) Manual criteria (18) : the primary tumor size, the extraparenchymal extension and the involvement of skin, the mandible or maxilla bone, the ear canal, the skull base, and the pterygoid plate. If each diagnostic modality predicted the malignant tumors in the affected gland and the pathologic tumor size within an error of 1 cm for the diameter, then this was considered as a true-positive for tumor size. The regional cervical nodes were also subdivided into the cervical lymph node levels (levels I-VI, the periparotid and infraparotid lymph node groups).
For the CT scans, a radiologist who specializes in interpreting head and neck sections determined the extent of the salivary gland lesion and the significance of the cervical lymph nodes, without having any knowledge of the clinical findings. First, the interpretation of the CT scans was focused on the primary lesions of the salivary gland. Salivary lesions with an abnormal enhancement pattern were evaluated to assess the tumor extent, according to the subsites. The regional lymph nodes of the head and neck region were also evaluated according to the accepted criteria (19) .
For PET/CT, 1 nuclear medicine physician, who was experienced in interpreting head and neck imaging for .5 y, reviewed the fused PET/CT images without having any knowledge of the clinical findings. The nuclear medicine physician first reviewed the images to determine any abnormal uptake of 18 F-FDG in the salivary gland and neck nodes by using the maximal uptake values with intensity that was higher than that of the surrounding tissues. An abnormal location and asymmetry of the 18 F-FDG uptake was also considered as an important diagnostic criterion for PET/CT. Their interpretation was then revised on the basis of the anatomic information provided by the combined PET/CT images. For example, a nonnodal focal uptake in a blood vessel or muscle that mimicked a lymph node was considered benign. A lymph node with low peripheral attenuation suggesting a fatty hilum on the CT image was considered benign even if it had a high 18 F-FDG uptake. On the contrary, a lymph node containing a lucent portion on the CT image and low 18 F-FDG uptake on the PET image that was suggestive of necrosis was considered malignant even if it had a low 18 F-FDG uptake.
Similar to the interpretation of the CT scans, a nuclear physician determined the status of each subsite from the information of the ''stand-alone'' PET/CT scans. The interpretation of each subsite was classified as malignant-positive, malignant-negative, or equivocal. During PET/CT, there were 2 equivocal subsites in the evaluation of primary tumors and 9 equivocal sites in the evaluation of distant metastasis. There was no equivocal lesion in the evaluation of the nodes at the neck level. During CT, 4 equivocal lesions were measured when evaluating the distant metastasis. The equivocal subjects were reclassified into malignant-positive or malignant-negative after separately reviewing the images by the same radiologists or the nuclear medicine physician.
Decision Making for Treatment
The Head and Neck Cancer Tumor Board decided the treatment plan for the salivary lesions after a review of the results of the clinical examinations and the CT scans. The team then reviewed the PET/CT images, and any changes in the decision making for treatments were recorded. The final treatment plans were determined after a discussion with each patient, and the available treatment options were outlined.
Statistical Analysis
The reference standards for describing the status of each subsite and the initial tumor stage were derived from the histopathologic results from the biopsies and the surgical excisions in 25 subjects. The clinical and radiologic follow-up for neck nodes and distant sites were also used as a reference in 8 patients.
We determined the sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic accuracy of CT and PET/CT for predicting the extent of disease using the subsite-based analysis that was described. Statistical differences between the imaging modalities were analyzed by using the McNemar test, and the 95% confidence levels were determined using Wilson's method. Two-tailed P values , 0.05 were considered to be statistically significant. The clinical decisions for treatment using CT alone and then adding PET/CT were recorded to register the impact of each diagnostic modality on patient care. The additional benefits provided by PET/CT were noted.
RESULTS

Diagnostic Values of Subsite-Based Analysis for High-Grade Salivary Cancer
The maximum SUV of the primary lesions ranged from 1.5 to 23.7, with a mean SUV 6 SD of 8.21 6 3.62 (Table 2) . A minimum SUV of 1.5 was noted for the adenoid cystic carcinoma at the submandibluar gland, and a maximum SUV of 23.7 was detected for the mucoepidermoid carcinoma at the submandibular gland.
Within the primary site, there was a total of 67 subsites as revealed by 37 PET/CT and CT scans that were then evaluated (Table 3 ). Of these, the size of the salivary tumors was analyzed by PET/CT and CT to predict the pathologic tumor size, and this was achieved to within an error of 1 cm for the diameter in 21 subjects. When comparing PET/CT and CT for predicting the pathologic primary tumors, CT had a sensitivity of 64.2%, a specificity of 80.0%, a PPV of 84.3%, a NPV of 57.1%, and a diagnostic accuracy of 70.1%; the corresponding values for the PET/CT scans were 85.7%, 100.0%, 100.0%, 80.6%, and 91.0%, respectively. Thus, the sensitivity, NPV, and overall diagnostic accuracy were each significantly higher for PET/CT than for CT, whereas the differences in the other parameters were close to being statistically significant. 
CT scan. But PET/CT showed a high SUV uptake at the same area, suggesting malignancy, and this was proven to be true on the surgical pathology. When imaging studies were performed for the evaluation of recurrence, it was more difficult to differentiate inflammation from recurrence. A patient who had surgical treatment and postoperative radiation therapy presented different results on CT and PET/CT during the follow-up (Fig. 2) . PET/CT correctly diagnosed the recurrence in this patient.
Eighty-six neck node analyses were done to determine the diagnostic values (Table 4) . For predicting cervical lymph node metastasis, CT had a sensitivity of 71.8%, a specificity of 94.4%, a PPV of 88.4%, a NPV of 85.0%, and a diagnostic accuracy of 86.0%; the corresponding values for the PET/CT scans were 100.0%, 96.3%, 94.1%, 100.0%, and 97.6%, respectively. Again, the sensitivity, NPV, and overall diagnostic accuracy were significantly higher for PET/CT than for CT for the evaluation of cervical metastasis (Table 4) . On the PET images, the maximum SUV of the neck nodes ranged from 1.4 to 27.2, with a mean SUV 6 SD of 7.07 6 5.36.
In the subject with recurrence at multiple cervical lymph nodes, PET/CT detected the metastatic lymph node at the right highest mediastinum, which made a surgical approach deep to that level necessary (Fig. 3) . CT failed to provide definitive information for the same lesion. 
Diagnostic Accuracy for Determination of TNM Tumor Stages of High-Grade Salivary Cancer
For predicting the TNM stages, CT had a diagnostic accuracy of 62.1%, as compared with 83.7% for the PET/ CT scans; thus, PET/CT was far superior to CT (P 5 0.03) ( Table 5 ).
The T and N classifications were determined separately for each diagnostic modality; however, the M classification was determined from the clinical examination, a routine simple chest x-ray, and the CT scans. In the case of PET/ CT, all T, N, and M classifications were determined solely by the results of PET/CT.
Impact on Clinical Treatment Planning
The clinical decision making with regard to treatment, as based on CT, was modified by adding the information gained from PET/CT in 16 of the 37 subjects we studied (43.2%) ( Table 6 ). In 5 patients, the extent of surgery indicated for their primary lesions was modified. In 3 of these patients, CT was not able to detect the primary lesions as malignant tumors. Therefore, the information obtained from PET/CT converted a conservative resection to a comprehensive resection of the primary tumor. For 1 patient, PET/CT detected the recurrence in the surgical bed after the initial surgery and radiation therapy, and this allowed salvage surgery to be undertaken. The PET/CT information led to decreasing the extent of surgery in 1 patient; thus, a radical parotidectomy was avoided, including that on the periparotid muscles. PET/CT correctly predicted a final T1 tumor, whereas CT had interpreted the T classification of this tumor as T4.
For the neck nodes, the PET/CT information changed an elective neck dissection regimen in 1 patient to a comprehensive neck dissection. Also for this patient, the peritumor regional lymph node groups (infraparotid and preparotid) were included in the extent of neck dissection, based on the results of the PET/CT scans.
In 8 subjects, PET/CT detected distant metastasis (lung, liver, bone, abdominal lymph nodes); therefore, the treatment was changed from a curative intent to a palliative setting.
DISCUSSION
The aim of this study was to investigate the role of integrated 18 F-FDG PET/CT for the management of salivary gland cancer, with special focus on tumors of a high-grade nature. We then compared PET/CT with contrast-enhanced CT. The results demonstrate that the PET/CT image data significantly improved the diagnostic accuracy for evaluating the extent of tumor and the tumor stages compared with CT alone for patients with high-grade salivary cancers. Several previous studies have concluded that 18 F-FDG PET is superior to conventional imaging modalities for the evaluation of salivary gland tumors or for distinguishing between benign and malignant masses (11) (12) (13) (14) . A recent report on the use of 18 F-FDG PET for the management of patients with salivary gland malignancies also concluded that it could have a significant role in the initial staging and monitoring after treatment (20) . However, these authors did not analyze the anatomic localization of the primary tumors on a subsite basis, as was done in our study; they used only the results of PET images.
In the present study, we used the subsite-based analysis rather than the T or N classification for more accurate anatomic evaluation. The T classification is based on the extent of involvement in different, anatomic subsites. We used the concept of subsites of the salivary gland that was taken from the AJCC classification. This made it easier to compare the diagnostic accuracy for the primary lesion using CT. As for the N classification, we also used a levelby-level analysis for the exact localization of nodal involvement. This subsite analysis of the primary tumors and the cervical nodes provided more useful information for treatment decisions-for example, the extent of surgery or the field of irradiation. For distant sites, we focused primarily on the presence or absence of distant metastasis, which was usually confirmed by subsequent imaging modalities (chest CT, bone MRI), biopsy, or follow-up data. As a result, interpretation of the anatomic extent and the metabolic rate of the tumors as well as a subsite-based analysis for surgical planning were all achieved. It also should be noted that the different histologic grades of salivary malignancies were included in a previous report, and this may have affected the interpretation of the PET images (20) .
The difference in the results of the previous studies on PET or PET/CT could be partially attributed to subjective characteristics. Thus, if we focus on distinguishing between malignant and benign salivary gland tumors, PET often fails, whereas PET can provide useful information for decision making with respect to the high metastatic potential of salivary gland cancer. In fact, when deciding on a treatment plan, distinguishing between benign tumor and malignant tumor is not too important because low-grade salivary gland cancers appear to show a good prognosis after conservative treatment and this is similar to the subjects with benign salivary tumors. However, for highgrade salivary gland cancers, accurate information on the tumor extent and its spread is more important for planning treatment. In the present study, we focused exclusively on high-grade salivary cancers, which would normally require more aggressive treatment; this is different from low-grade salivary cancers. By this means, we were able to show the impact of a PET/CT examination for patients with highgrade salivary cancers.
There was wide range of maximum SUV values (Table  2) , and we assumed that it might be partially due to the variable pathologic characteristics of the salivary cancers, even though they were all categorized as high-grade. Except for the adenoid cystic carcinomas, which are characterized as being relatively slow growing, the other high-grade salivary pathologies showed SUVs of .5.0. However, the minimum SUV of 1.5 (adenoid cystic carcinoma) was asymmetrically detected in the submandibular area, which raised the suggestion of malignancy in the submandibular gland. One case of mucoepidermoid carcinoma had an SUV of 23.7, and the size of the tumor reached 6.5 cm. In this subject, the high SUV was attributable to the huge size of the primary tumor. The sensitivity and specificity of PET/CT was 85.7%-100.0% and 96.3%-100.0%, respectively, with respect to the subsite-based and node level-based analysis. These values were similar to the values of the previous reports on PET usage for primary tumors, but our values were slightly higher for neck nodes, compared with the other reports (20) . These differences may be explained on the basis of the subsite-based analysis, which used stricter criteria. For example, prediction of the pathologic size as well as detection of malignant tumors was considered to be true-positive. For evaluating the neck nodes, the alleged CT criteria for distinguishing between benign and malignant cervical lymph nodes-such as the presence of necrotic nodes and nodes with a peripheral fatty hilum-contributed to the improved accuracy using PET/CT for evaluating the cervical nodes combined with the SUV assessment (19, 21) . This suggests that the CT data are also helpful in the interpretation of PET/CT images for the patients with salivary cancer.
Even though PET/CT showed diagnostic superiority for the management of high-grade salivary cancers, the combined interpretation of contrast-enhanced CT and PET/CT can provide more accurate information about the extent of disease. Using combined interpretation of the contrastenhanced CT with PET/CT side by side, the sensitivity, specificity, and diagnostic accuracy for the primary tumors on the subsite-based analysis were 88.1%, 100%, and 92.6%, respectively. Similarly, the corresponding values for the neck nodes on the level-by-level analysis were all 100%. Therefore, integrated PET along with contrastenhanced CT may give the best diagnostic results for highgrade salivary malignancies.
With respect to tumor staging, PET/CT was correct in predicting 31 of 37 subjects (83.7%), whereas CT was correct in only 23 of 37 subjects (62.1%). For the 10 subjects in which CT had incorrectly predicted the tumor staging, the results of PET/CT were correct, as was ultimately assessed by the pathologic results and follow-up data. There were only 2 subjects for which CT was correct and PET/CT was incorrect for the staging of a tumor, whereas for 4 subjects, neither modality provided an accurate estimate.
The PET/CT method has an additional advantage in that it is a whole-body imaging procedure, which may be useful in detecting distant metastases or a second cancer (22, 23) . The treatment outcome of our study showed the frequent occurrence of distant metastasis in high-grade salivary cancer patients (18/33 subjects, 54.5%). Moreover, when PET/CT was performed, it was successful in detecting a distant metastasis, as compared with the conventional metastasis detection methods. If PET/CT could fully replace the conventional approach for detecting distant metastasis or a double primary cancer, the high cost of PET/CT would be acceptable and justified.
More importantly, the information from the PET/CT scans had a major impact on the clinical treatment planning in about 40% of the subjects. For the high-grade salivary gland malignancies, only surgical resection guarantees curative treatment, and the role of other treatments, such as chemotherapy or radiotherapy, is confined to an adjuvant or palliative intent. Therefore, the exact decision on the operability is of utmost importance when evaluating those patients with high-grade salivary gland malignancies. Unlike previous reports, the present study analyzed the impact of PET/CT on the clinical treatment planning and revealed that 21.6% of the patients were proven to be inoperable because of their distant metastasis; thus, unnecessary surgeries could be avoided for these patients. Even for the operable patients, the increased anatomic accuracy of PET/CT changed the extent of surgery on the primary lesions and neck nodes (13.5% and 8.1%, respectively); such findings helped enhance the possibility of cure for patients with high-grade salivary gland malignancies.
CONCLUSION
Our results indicate that 18 F-FDG PET/CT provides superior diagnostic accuracy for evaluating the extent of tumors and for tumor staging, as compared with CT scans, for the patients with high-grade salivary cancer. Moreover, the use of PET/CT has a major positive impact on the clinical decision-making process for those patients who have these cancers.
